Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...

In the wake of the 2024 U.S. elections, stakeholders in the life sciences and health care industry are intensely focused on the policy ...

A tide change is rippling across healthcare. As industry leaders converged on San Francisco for the 2025 JP Morgan Healthcare conference, they echoed optimism about a renewed stability in healthcare, ...

Another year at the J.P. Morgan Healthcare Conference is in the books. | While major payers skipped out on this year’s event, ...

UNC Health and Duke Health formed a joint venture to build a 500-bed, free-standing children's hospital in the Piedmont, ...

JPMorgan Chase named Curtis Reed on Tuesday as chief of the largest U.S. lender's government banking and healthcare, higher ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Pfizer stock bounded off its 50-day line on Monday after avoiding a battle with activist investor Starboard Value — for now.

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

Surgery centers are the next focus, President and CEO Martin Bonick told a recent industry conference. But that push is more ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...